How many stocks are there of CSL?
The current number of stocks of CSL is 483.89 M undefined.
CSL Stocks 2024
CSL Stocks
483.89 M
Ticker
CSL.AX
ISIN
AU000000CSL8
WKN
890952
In 2024, CSL had 483.89 M outstanding stocks, a 0% change from the 483.89 M stocks in the previous year.
The CSL Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2030e | 483.89 |
| 2029e | 483.89 |
| 2028e | 483.89 |
| 2027e | 483.89 |
| 2026e | 483.89 |
| 2025e | 483.89 |
| 2024e | 483.89 |
| 2023 | 483.89 |
| 2022 | 468.75 |
| 2021 | 456.2 |
| 2020 | 455.61 |
| 2019 | 454.03 |
| 2018 | 453.88 |
| 2017 | 456.37 |
| 2016 | 463.12 |
| 2015 | 473.17 |
| 2014 | 485.6 |
| 2013 | 500.3 |
| 2012 | 520.3 |
| 2011 | 541.8 |
| 2010 | 568.6 |
| 2009 | 597.7 |
| 2008 | 553.3 |
| 2007 | 551.4 |
| 2006 | 571.3 |
| 2005 | 590.8 |
| 2004 | 536.6 |
CSL shares outstanding AU000000CSL8 · 890952
The number of shares was CSL in 2023 — This indicates how many shares 483.886 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue CSL earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates CSL's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of CSL’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CSL's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 536.6 M Aktien |
| 2005 | 590.8 M Aktien |
| 2006 | 571.3 M Aktien |
| 2007 | 551.4 M Aktien |
| 2008 | 553.3 M Aktien |
| 2009 | 597.7 M Aktien |
| 2010 | 568.6 M Aktien |
| 2011 | 541.8 M Aktien |
| 2012 | 520.3 M Aktien |
| 2013 | 500.3 M Aktien |
| 2014 | 485.6 M Aktien |
| 2015 | 473.17 M Aktien |
| 2016 | 463.12 M Aktien |
| 2017 | 456.37 M Aktien |
| 2018 | 453.88 M Aktien |
| 2019 | 454.03 M Aktien |
| 2020 | 455.61 M Aktien |
| 2021 | 456.2 M Aktien |
| 2022 | 468.75 M Aktien |
| 2023 | 483.89 M Aktien |
| 2024e | 483.89 M Aktien |
| 2025e | 483.89 M Aktien |
| 2026e | 483.89 M Aktien |
| 2027e | 483.89 M Aktien |
| 2028e | 483.89 M Aktien |
| 2029e | 483.89 M Aktien |
| 2030e | 483.89 M Aktien |
CSL Aktienanalyse
What does CSL do?
CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating CSL's Shares Outstanding
CSL's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in CSL’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding CSL’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in CSL’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about CSL Stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of CSL are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of CSL evolved in recent years?
The number of shares of CSL has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. CSL as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of CSL?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does CSL pay?
Over the past 12 months, CSL paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CSL is expected to pay a dividend of 3.92 USD.
What is the dividend yield of CSL?
The current dividend yield of CSL is .
When does CSL pay dividends?
CSL pays a quarterly dividend. This is distributed in the months of October, April, October, April.
How secure is the dividend of CSL?
CSL paid dividends every year for the past 27 years.
What is the dividend of CSL?
For the upcoming 12 months, dividends amounting to 3.92 USD are expected. This corresponds to a dividend yield of 2 %.
In which sector is CSL located?
CSL is assigned to the 'Health' sector.
Wann musste ich die Aktien von CSL kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of CSL from 4/3/2024 amounting to 1.799 USD, you needed to have the stock in your portfolio before the ex-date on 3/11/2024.
When did CSL pay the last dividend?
The last dividend was paid out on 4/3/2024.
What was the dividend of CSL in the year 2023?
In the year 2023, CSL distributed 3.257 USD as dividends.
In which currency does CSL pay out the dividend?
The dividends of CSL are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The CSL stock can be added to a savings plan with the following providers: Consorsbank
Andere Kennzahlen von CSL
Our stock analysis for CSL Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CSL Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
